The European Robotic Spinal Instrumentation (EUROSPIN) Study (EUROSPIN)

July 7, 2020 updated by: Marc Schröder

The European Robotic Spinal Instrumentation (EUROSPIN) Study: A European Prospective Multicenter Multinational Pragmatic Trial on Robot-guided Versus Navigated Versus Freehand Pedicle Screw Fixation

In a multinational prospective study, preoperative, intraoperative, perioperative and follow-up data on patients receiving thoracolumbar pedicle screw placement for degenerative disease or infections or tumors will be collected. The three arms consist of robot-guided (RG), navigated (NV), or freehand (FH) screw insertion.

Study Overview

Detailed Description

Introduction A decade ago, minimally invasive surgery (MIS) was considered a promising development in spine surgery, yet the value of the pioneering technologies was questionable. With the growing number of experienced MIS surgeons, the influx of evidence in favour of MIS is rapidly increasing. This makes a compelling argument towards MIS offering distinct clinical benefits over open approaches in terms of blood loss, length of stay, rehabilitation, cost-effectiveness and perioperative patient comfort. Due to the limited or inexistent line-of-sight in MIS procedures, surgeons need to rely on imaging, navigation, and guidance technologies to operate in a safe and efficient manner. Therefore, a plethora of new and ever improving navigational systems have been developed. These systems allow a consistent level of safety and accuracy, on par with results achieved by very experienced free hand surgeons, with a reasonably short learning curve. Computer-based navigation systems were first introduced to spine surgery in 1995 and while they have been long established as standards in certain cranial procedures, they have not been similarly adopted in spine surgery.

Designed to overcome some of the limitations of navigation-based technologies, robot-guided surgery has become commercially available to surgeons worldwide, like SpineAssist® (Mazor Robotics Ltd. Caesarea, Israel) and the recently launched ROSA™ Spine (Zimmer-Biomet, Warsaw, Indiana, USA). These systems are rapidly challenging the gold standards. SpineAssist®, and its upgraded version, the Renaissance®, provides a stable drilling platform and restricts the surgeon's natural full range of motion to 2 degrees of freedom (up/down motion and yaw in the cannula). The system's guidance unit moves into the trajectory based on exact preoperative planning of pedicle screws, while accounting for changes in intervertebral relationships such as due to distraction, cage insertion or changes between the supine patient position in the preoperative CT and the prone patient on the operating table. Published evidence on robot-guided screw placement has demonstrated high levels of accuracy with most reports ranging around 98% of screws placed within the pedicle or with a cortical encroachment of less than 2 mm.4 Although the reliability and accuracy of robot-guided spine surgery have been established, the actual benefits for the patient in terms of clinical outcomes and revision surgeries remain unknown. We have recently conducted cohort studies that showed some evidence that robotic guidance lowers the rate of intraoperative screw revisions and implant related reoperations compared to free hand procedures, while achieving comparable clinical outcomes. We now want to assess these factors, among others, on a higher level of evidence. We aim to conduct a prospective, multicenter, multinational controlled trial comparing clinical and patient reported outcomes of robotic guided (RG) pedicle screw placement vs. navigated (NV) vs. free hand (FH) pedicle screw placement using pooled data from three centers.

Study Design The European Robotic Spinal Instrumentation (EUROSPIN) study is a prospective, international, multicentre, pragmatic, open-label, non-randomized controlled trial comparing the effectiveness of three techniques for pedicle screw instrumentation, namely RG, NV (CT-, O-Arm, or 3DFL-based), and FH. Following the baseline evaluation, patients will receive one of the three treatments, and will subsequently be followed up for 24 months (Figure 1). The primary analysis will be conducted using the 12-month data.

Sample Size Calculation It was determined that, to detect an intergroup difference of 5% in the primary endpoint, 205 patients are required per group to achieve a power of 1 - beta = 0.8 at alpha = 0.05. The incidence rates were based on the published literature, with an approximated incidence rate of the primary endpoint of 0% for the intervention and 5% for the control group. Because the study protocol is in line with the normal clinical follow-up of most centers, a low dropout rate is expected. This led to a minimum total sample size of 615 patients.

Monitoring An epidemiologist from the sponsor institution will organize an initiation monitor visit at every participating center before starting recruitment. This monitor visit will check whether all study staff are properly trained and the delegation of tasks are well documented (complete Investigator Site File, training and delegation logs). An additional audit will be carried out at 6 months after initiation of recruitment to check whether source documentation and eCRF documentation is similar. Throughout the entire study additional queries by the monitor are send to the investigator in the data capturing system to ensure proper data capturing.

Study Type

Observational

Enrollment (Anticipated)

615

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Innsbruck, Austria
        • Not yet recruiting
        • Medical University of Innsbruck
        • Contact:
          • Pierre-Pascal Girod, MD
        • Contact:
          • Nikolaus Kögl, MD, MSc
      • Amiens, France
        • Not yet recruiting
        • Amiens University Hospital
        • Contact:
          • Michel Lefranc, MD, PhD
      • Paris, France
        • Recruiting
        • La Pitié Salpêtrière Hospital
        • Contact:
          • Aymeric Amelot, MD
      • Berlin, Germany
        • Not yet recruiting
        • Helios Klinikum Berlin-Buch
        • Contact:
          • Yu-Mi Ryang, MD
      • Dortmund, Germany
        • Not yet recruiting
        • Ortho-Klinik Dortmund
        • Contact:
          • Farman Hedayat, MD
        • Contact:
          • Sophie Urbanski
      • Göttingen, Germany
        • Not yet recruiting
        • Universitatsmedizin Gottingen
        • Contact:
          • Christoph Bettag, MD
        • Contact:
          • Bawarjan Schatlo, MD
      • Munich, Germany
        • Not yet recruiting
        • Klinikum rechts der Isar
        • Contact:
          • Sandro M Krieg, MD, MBA
      • Paderborn, Germany
        • Not yet recruiting
        • St Josef Brothers Hospital
        • Contact:
          • Carsten G Schneekloth, MD
      • Groningen, Netherlands
        • Not yet recruiting
        • Martini Hospital
        • Contact:
          • Mike Abu Saris, MD
      • Naarden, Netherlands, GE
      • the Hague, Netherlands
        • Not yet recruiting
        • MC Haaglanden
        • Contact:
          • Jasper FC Wolfs, MD
      • Geneva, Switzerland
        • Not yet recruiting
        • HUG Geneva
        • Contact:
          • Enrico Tessitore, MD
      • Lausanne, Switzerland
        • Not yet recruiting
        • Clinique de la Source
        • Contact:
          • Duccio Boscherini, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients receiving thoracolumbar transpedicular screw placement for degenerative pathologies (stenosis, spondylolisthesis, degenerative disc disease, recurrent disc herniation), infections, fractures, trauma, or tumors.

Description

Inclusion Criteria

  • Informed consent
  • Thoracolumbar pedicle screw placement
  • Indication for surgery: Degenerative pathologies (stenosis, spondylolisthesis, degenerative disc disease, recurrent disc herniation), infections, tumors, fractures, trauma
  • Age ≥ 18

Exclusion Criteria

  • Deformity surgery
  • >5 index levels

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Robot-Guided Transpedicular Instrumentation
This arm will comprise all patients that receive transpedicular instrumentation by use of a robotic guidance system (SpineAssist or Renaissance, Mazor Robotics, Ltd., Caesarea, Israel or ROSA Spine, Medtech, Montpellier, France).
Transpedicular screw placement and instrumentation
Navigated Transpedicular Instrumentation
This arm will comprise all patients that receive transpedicular instrumentation by use of navigation (computer assistance using CT, O-arm or 3D-fluoroscopic imaging).
Transpedicular screw placement and instrumentation
Freehand Transpedicular Instrumentation
This arm will comprise all patients that receive transpedicular instrumentation by use of the conventional freehand technique.
Transpedicular screw placement and instrumentation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Revision surgery for a malpositioned pedicle screw
Time Frame: 12 months
We defined the primary endpoint as required revision surgery for a malpositioned or loosened pedicle screw within the first postoperative year.
12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Intraoperative screw revision
Time Frame: Intraoperative
Revision or redirection of a placed screw during the same general anesthesia session
Intraoperative
Duration of Surgery
Time Frame: Intraoperative
Duration of Surgery in minutes
Intraoperative
Length of Hospital Stay
Time Frame: Through hospital stay (From admission to discharge of the hospital stay in which the primary surgery was carried out)
Length of Hospital Stay in days (Defined as from admission to discharge, during the hospital stay in which the primary surgery was carried out)
Through hospital stay (From admission to discharge of the hospital stay in which the primary surgery was carried out)
Radiation Dose (DAP)
Time Frame: Intraoperative
Radiation Dose as DAP (Dose Area Product, cGy cm2)
Intraoperative
Estimated Blood Loss
Time Frame: Intraoperative
Estimated Blood Loss (ml)
Intraoperative
Need for blood transfusion
Time Frame: Through hospital stay (From admission to discharge of the hospital stay in which the primary surgery was carried out)
Need for blood transfusion during the hospital stay (Defined as from admission to discharge, during the hospital stay in which the primary surgery was carried out)
Through hospital stay (From admission to discharge of the hospital stay in which the primary surgery was carried out)
Intraoperative Complications
Time Frame: 0 weeks
Intraoperative Complications
0 weeks
Postoperative Complications
Time Frame: 6 weeks
Postoperative Complications
6 weeks
EQ-5D-3L
Time Frame: 2 years

EQ-5D-3L (Health-related quality of life) EuroQOL-five dimensions 3-level version measures health-related quality of life.

The scale is subdivided into an index, ranging from 0 to 1 and normalized to population-specific values, and a "thermometer" or visual analogue scale, ranging from 0 to 100.

The two subscores are not combined towards a single score. Higher values represent a better health-related quality of life in both subscores.

2 years
NRS back pain severity
Time Frame: 2 years
Numeric Rating Scale (NRS) of back pain severity The scale ranges from 0 to 10. Only integers are available to choose from. Higher values represent a higher amount of pain. There are no subscales.
2 years
NRS leg pain severity
Time Frame: 2 years
Numeric Rating Scale (NRS) of leg pain severity The scale ranges from 0 to 10. Only integers are available to choose from. Higher values represent a higher amount of pain. There are no subscales.
2 years
Oswestry Disability Index
Time Frame: 2 years
Oswestry Disability Index (ODI) for functional impairment
2 years

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Frequency of use of analgetics
Time Frame: 2 years
Frequency of use of analgetics (daily/weekly/not regularly)
2 years
Satisfaction with symptoms
Time Frame: 2 years
Satisfaction with symptoms (satisfied/neutral/dissatisfied)
2 years
Smoking status
Time Frame: 2 years
Smoking status (active/ceased/never)
2 years
Working status
Time Frame: 2 years
Working status (able to work/unable to work)
2 years
Return to work
Time Frame: 2 years
Return to work (number of weeks/not yet)
2 years
Overall rate of reoperations
Time Frame: 2 weeks
Overall rate of reoperations
2 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: Victor E Staartjes, BMed, Department of Neurosurgery, Bergman Clinics
  • Principal Investigator: Marc L Schröder, MD, PhD, Department of Neurosurgery, Bergman Clinics
  • Study Director: Paulien M van Kampen, PhD, Department of Epidemiology, Bergman Clinics

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 20, 2018

Primary Completion (Anticipated)

September 1, 2021

Study Completion (Anticipated)

September 1, 2023

Study Registration Dates

First Submitted

January 7, 2018

First Submitted That Met QC Criteria

January 7, 2018

First Posted (Actual)

January 16, 2018

Study Record Updates

Last Update Posted (Actual)

July 8, 2020

Last Update Submitted That Met QC Criteria

July 7, 2020

Last Verified

July 1, 2020

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Degenerative Disc Disease

Clinical Trials on Transpedicular Instrumentation

3
Subscribe